



December 10<sup>th</sup>, 2021

Luxna Biotech Co., Ltd.

## **Announcing the Milestone Achievement based on the Technology License Agreement with Aligos Therapeutics**

OSAKA, JAPAN, November 30<sup>th</sup>, 2021 – Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter “Luxna”) today announced that it had received a payment from Aligos Therapeutics, Inc. (Chairman and CEO Lawrence Blatt, Headquarters: SOUTH SAN FRANCISCO, CA, U.S.A., hereinafter “Aligos”) in connection with a development milestone event specified in the technology license agreement which was entered into during December 2018 between Luxna and Aligos for the use of Luxna’s breakthrough nucleic acid technology (hereinafter “Luxna XNAs technology”) (hereinafter “this agreement”).

This agreement grants to Aligos the exclusive license of the Luxna XNAs technology for the development of oligonucleotide therapeutics for use against specified targets or indications. The undisclosed milestone amount was paid following Aligos’ dosing of the first subject in a Phase 1 clinical trial of its antisense oligonucleotide (ASO) for hepatitis B virus (ALG-020572).

### **About Aligos Therapeutics, Inc.**

Aligos is a drug discovery biotech company developing novel drugs focused on viral infections and liver diseases, and has advanced four compounds into clinical development since being founded in 2018.

<https://www.aligos.com/>

### **About ALG-020572**

ALG-020572 is a proprietary ASO therapeutic candidate that is designed to reduce circulating hepatitis B virus surface antigen levels, and that incorporates the Luxna XNAs technology to improve its pharmacological characteristics. It is hoped that a combination regimen containing ALG-020572 could achieve higher rates of functional cure for chronic hepatitis B patients. The Phase I clinical trial is a two-part umbrella protocol that includes dosing of healthy volunteers and patients with chronic hepatitis B. Please see the following press release for details of the study.

<https://investor.aligos.com/news-releases/news-release-details/aligos-therapeutics-begins-dosing-antisense-oligonucleotide-drug>

### **About Luxna Biotech Co., Ltd.**

Luxna is a biotech to be founded to support patients who are suffering from diseases and to create oligonucleotide therapeutics by installing the nucleic acid pharmaceutical element technologies accumulated in Osaka University that promote safer and more effective oligonucleotide therapeutics in the clinical setting. Luxna

actively promotes co-development with some pharmaceutical companies and in-house drug discovery with ASOs as our main development drugs.

#### About Luxna XNAs technology

Luxna XNAs technology collectively means an innovative nucleic acid group of AmNA, scpBNA, GuNA and 5'-CP accumulated in Professor Obika's laboratory (Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry). Luxna XNAs technology could make available ASOs that satisfy requirements for both a high level of activity and low toxicity, and to take advantage of its characteristics of high affinity for mRNA and reduced hepatotoxicity.

#### Contact

Luxna Biotech Co., Ltd.

E-mail: [info@luxnabiotech.co.jp](mailto:info@luxnabiotech.co.jp) HP : <https://luxnabiotech.co.jp/>